Finding a kidney tumour on a scan can raise many questions. Is it cancer? Has it spread? Will the whole kidney need to be removed?
Not every kidney tumour is cancerous. A kidney mass may be benign or malignant, and further assessment helps clarify its nature. “Stage 1” describes the extent of a kidney cancer; it does not apply automatically to every small growth found on a scan.
This article explains stage 1 renal cell carcinoma, the most common type of kidney cancer in adults, and the factors that guide management.
Stage 1 renal cell carcinoma means the tumour:
Its TNM stage is T1 N0 M0. The T1 category is divided according to size:
| Category | Tumour size and extent |
|---|---|
| T1a | 4 cm or smaller, confined to the kidney. |
| T1b | Larger than 4 cm but no larger than 7 cm, confined to the kidney. |
Size alone does not determine the stage. A smaller tumour that extends into certain blood vessels or surrounding tissues may have a higher stage.
Always Cancer?
No. Benign kidney tumours include angiomyolipomas and oncocytomas. Fluid-filled kidney cysts are another type of finding and require interpretation according to their imaging features.
Some masses can be characterised confidently on imaging; others remain uncertain. A specialist may recommend additional imaging, a biopsy or another management approach depending on whether the result would change care.
A report describing a “renal mass” or “suspicious lesion” should therefore be discussed before assuming a confirmed cancer diagnosis.
For related information, read about kidney tumours.
Early kidney cancer may cause no symptoms. A tumour may be discovered during imaging performed for an unrelated reason.
Possible symptoms of kidney cancer include:
These findings are not specific to cancer and cannot establish the stage. Blood in urine, for example, can also occur with stones or infection and needs assessment.
Assessment usually begins with the scan findings, medical history, examination and kidney function.
| Assessment | What it may help clarify |
|---|---|
| Medical history | Symptoms, previous conditions, medicines and family history. |
| Blood tests | Kidney function and other relevant abnormalities. |
| Urine testing | Blood or other urinary findings. |
| CT or MRI | The mass’s characteristics, location and extent. |
| Selected biopsy | Tissue information that may guide management. |
Contrast-enhanced imaging is often important, but the choice of investigation considers kidney function, allergies and other circumstances.
A biopsy is not required before surgery in every case. It may be useful when tissue information would influence the decision, including consideration of surveillance or ablation.
The stage estimated from examination and imaging is called the clinical stage. Examination of surgically removed tissue may provide a more precise pathological stage.
Management considers more than tumour size. Relevant factors include its position, imaging characteristics, kidney function, the other kidney’s health, surgical risk and the person’s preferences.
Partial nephrectomy removes the tumour while preserving the remaining kidney.
It is generally preferred for T1 renal cell carcinoma when technically feasible and oncologically appropriate. Preserving kidney tissue is an important consideration, particularly for people with reduced kidney function or a single functioning kidney.
Possible complications include bleeding, urine leakage and changes in kidney function. Suitability depends on the individual case.
Radical nephrectomy removes the affected kidney. It may be considered when partial nephrectomy is unsuitable because of tumour complexity, location or other clinical factors.
The decision should include the expected effect on overall kidney function and the alternatives available. A stage 1 diagnosis does not automatically mean that the whole kidney must be removed.
Active surveillance involves scheduled imaging and clinical review, with treatment reconsidered if relevant changes occur.
It may be appropriate for selected small renal masses, particularly when other health conditions or treatment risks influence the balance of benefit and harm. It requires a defined follow-up plan and should not be confused with ignoring the finding.
Thermal ablation uses techniques such as freezing or heating to destroy tumour tissue. It may be considered for selected small tumours, including circumstances where surgery carries additional risk.
Tumour location and size affect suitability. Tissue diagnosis and imaging follow-up are important parts of planning.
Systemic treatment is not routinely required for every stage 1 renal cell cancer. Any recommendation for additional treatment depends on the final diagnosis, pathological findings and recurrence risk.
Treatment for localised kidney cancer is often undertaken with curative intent. However, an individual outcome cannot be guaranteed.
Prognosis depends on factors including tumour subtype, grade, stage, treatment findings and overall health. Stage describes the cancer’s extent; grade describes features of the cells under the microscope.
Even after apparently complete treatment, follow-up remains important because recurrence is possible.
Follow-up can help assess:
The timing and type of imaging should reflect recurrence risk, treatment and kidney function. There is no single schedule suitable for every patient.
For broader background, read the beginner’s guide to urinary health.
Bring the scan images, report, previous investigations and medicine list. Useful questions include:
It measures 7 cm or less and remains confined to the kidney, without regional lymph-node or distant spread. Size must be interpreted alongside the tumour’s extent.
No. Early kidney cancer may cause no symptoms and may be discovered incidentally.
No. Benign tumours and cysts can occur. Imaging and, in selected cases, tissue assessment help clarify the diagnosis.
Not necessarily. Partial nephrectomy may be appropriate. The choice depends on the tumour and the person’s kidney function and health.
No. Biopsy is selected when its findings are likely to influence care. Imaging may provide enough information to plan surgery in some cases.
Yes, in selected circumstances. Active surveillance requires scheduled review and clear criteria for reconsidering treatment.
Yes. Follow-up assesses recovery, kidney function and possible recurrence. Its frequency depends on individual risk and treatment findings.
Stage 1 kidney cancer is confined to the kidney and measures no more than 7 cm. Assessment must first clarify the nature and extent of the mass, because not every kidney tumour is malignant.
Management may involve kidney-preserving surgery, removal of the kidney, surveillance or ablation in selected circumstances. Decisions should balance cancer control, kidney function, treatment risks and individual preferences.
Medical disclaimer: This article provides general educational information and does not replace personalised medical advice, diagnosis or treatment. Kidney mass assessment and management require review of individual clinical findings.